Loading...
XNASENLV
Market cap27mUSD
Dec 24, Last price  
1.26USD
1D
1.61%
1Q
-13.70%
Jan 2017
-75.77%
IPO
-81.74%
Name

Enlivex Therapeutics Ltd

Chart & Performance

D1W1MN
XNAS:ENLV chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
39.55%
Rev. gr., 5y
%
Revenues
0k
000000002,277,000000
Net income
-29m
L-31.45%
-229,000-1,145,000-7,022,000-15,365,000-16,022,000-5,945,000-4,242,000-10,149,000-13,863,000-9,648,000-42,407,000-29,068,000
CFO
-24m
L-1.80%
-149,000-865,000-4,409,000-13,249,000-15,486,000-6,352,000-3,161,000-7,041,000-11,007,000-17,542,000-23,953,000-23,523,000

Profile

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
URL
https://www.enlivex.com/
IPO date
Jul 30, 2014
Employees
71
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
Cost of revenue
26,209
26,172
19,667
Unusual Expense (Income)
NOPBT
(26,209)
(26,172)
(19,667)
NOPBT Margin
Operating Taxes
11,347
(4,820)
Tax Rate
NOPAT
(26,209)
(37,519)
(14,847)
Net income
(29,068)
-31.45%
(42,407)
339.54%
(9,648)
-30.40%
Dividends
Dividend yield
Proceeds from repurchase of equity
360
150
53,174
BB yield
-0.72%
-0.21%
-47.64%
Debt
Debt current
346
653
617
Long-term debt
1,718
4,847
6,006
Deferred revenue
Other long-term liabilities
Net debt
(25,564)
(42,928)
(77,510)
Cash flow
Cash from operating activities
(23,523)
(23,953)
(17,542)
CAPEX
(236)
(8,122)
(1,625)
Cash from investing activities
(25,968)
62,524
(38,408)
Cash from financing activities
360
150
60,982
FCF
(14,618)
(44,200)
(20,926)
Balance
Cash
27,320
48,121
84,130
Long term investments
308
307
3
Excess cash
27,628
48,428
84,133
Stockholders' equity
(108,855)
(79,807)
(48,757)
Invested Capital
139,971
141,495
139,802
ROIC
ROCE
EV
Common stock shares outstanding
18,574
18,395
17,860
Price
2.70
-31.43%
3.94
-37.00%
6.25
-25.86%
Market cap
50,151
-30.76%
72,430
-35.11%
111,623
0.55%
EV
24,587
29,502
34,113
EBITDA
(25,374)
(25,395)
(19,121)
EV/EBITDA
Interest
14
5,263
328
Interest/NOPBT